XTX Topco Ltd Increases Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Key Points

• XTX Topco Ltd significantly increased its holdings in Ironwood Pharmaceuticals by 1,104.4% in Q1, acquiring over 506,000 additional shares, bringing its total to approximately 552,613 shares valued at $812,000.
• Ironwood Pharmaceuticals recently reported a loss of $0.14 EPS for the quarter, missing the consensus estimate, with revenues of $41.14 million compared to a forecast of $67.02 million.
• Analyst ratings are mixed, with seven analysts giving a "hold" rating and two a "buy" rating, while the average price target for the stock is $4.78.

XTX Topco Ltd raised its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 1,104.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 552,613 shares of the biotechnology company's stock after acquiring an additional 506,732 shares during the quarter. XTX Topco Ltd owned approximately 0.34% of Ironwood Pharmaceuticals worth $812,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IRWD. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter valued at about $36,000. Simplicity Wealth LLC bought a new stake in Ironwood Pharmaceuticals during the 1st quarter valued at approximately $45,000. Envestnet Asset Management Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $50,000. Boothbay Fund Management LLC bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $57,000. Finally, Y Intercept Hong Kong Ltd lifted its stake in shares of Ironwood Pharmaceuticals by 162.6% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company's stock valued at $58,000 after purchasing an additional 24,635 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Jefferies Financial Group reiterated a "hold" rating and issued a $0.70 price target (down from $8.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th. Craig Hallum lowered shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Citizens Jmp cut shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Finally, Leerink Partners lowered their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $4.78.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD traded down $0.02 during midday trading on Monday, reaching $0.75. 1,127,465 shares of the company's stock traded hands, compared to its average volume of 1,251,343. Ironwood Pharmaceuticals, Inc. has a one year low of $0.53 and a one year high of $6.31. The company has a market cap of $121.45 million, a price-to-earnings ratio of -3.75 and a beta of 0.33. The stock has a 50 day moving average of $0.72 and a 200 day moving average of $1.25.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. The company had revenue of $41.14 million for the quarter, compared to analysts' expectations of $67.02 million. Sell-side analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.